Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of…
Articles by Marisa Wexler, MS
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary…
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis…
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation…
The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis…
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring…
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with…
An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical…
Starting this week and over the coming months, the Pulmonary Fibrosis Foundation (PFF) will be hosting the PFF Walk…